A clinical trial adriamycin (NSC 123127) in advanced sarcomas

22 patients with advanced sarcomas received adriamycin, 20--25 mg/m2/day for three days each three weeks. Two patients manifested objective response for a median of five months. Eight patients had stable disease for a median of three months. Nausea and vomiting occurred in 21 of 22 patients; leukopenia in eleven of 22; thrombocytopenia in four of 22. There was no clinically significant cardiotoxicity. Our study indicates that this regimen for adriamycin was relatively ineffective in the management of these inoperable or metastatic malignancies.